For citations:
Motzer R., George S., Merchan J.R., Hutson T.E., Song X., Perini R.F., Xie R., Bapat U., Puente J. Characterization and management of adverse reactions from the CLEAR study in advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab. Cancer Urology. 2023;19(2):29-40. (In Russ.) https://doi.org/10.17650/1726-9776-2023-19-2-29-40
Email this article 